International Journal of
Reproductive Biomedicine
Wed, May 8, 2024
[Archive]
Volume 14, Issue 4 (4-2016)
IJRM 2016, 14(4): 271-274 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Miresmaeili S M, Kordi Tamandani D M, Kalantar S M, Moshtaghioun S M. Haplotype analysis of BRCA1 intragenic markers in Iranian patients with familial breast and ovarian cancer. IJRM 2016; 14 (4) :271-274
URL: http://ijrm.ir/article-1-741-en.html
URL: http://ijrm.ir/article-1-741-en.html
Seyed Mohsen Miresmaeili1 
, Dor Mohammad Kordi Tamandani * 2, Seyed Mehdi Kalantar3 , Seyed Mohammad Moshtaghioun4
, Dor Mohammad Kordi Tamandani * 2, Seyed Mehdi Kalantar3 , Seyed Mohammad Moshtaghioun4
1- Department of Biology, Faculty of Science, University of Sistan and Baluchestan, Zahedan, Iran
2- Department of Biology, Faculty of Science, University of Sistan and Baluchestan, Zahedan, Iran , dor_kordi@ yahoo.com
3- Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
4- Department of Biology, Faculty of Sciences, University of Yazd, Yazd, Iran
2- Department of Biology, Faculty of Science, University of Sistan and Baluchestan, Zahedan, Iran , dor_kordi@ yahoo.com
3- Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
4- Department of Biology, Faculty of Sciences, University of Yazd, Yazd, Iran
Full-Text [PDF 382 kb]
(645 Downloads)
| Abstract (HTML) (2522 Views)
Full-Text: (311 Views)
Introduction
Breast cancer is responsible for a large amount of mortality rate in women worldwide. Hereditary Breast and Ovarian Cancer is a syndrome that increases the lifetime risk for developing breast and/or ovarian cancer and other malignancies in women. Inheritance of this syndrome is usually based on germ-line mutation in one allele of either the Breast Cancer Type 1 Susceptibility (BRCA1) or Breast Cancer Type 2 Susceptibility (BRCA2) genes (1-4). In American society, more than 1.5 million new breast cancer cases occurred in 2014 (5). In Iranian society, lifetime prevalence of breast cancer is one in eight female cases and the breast cancer patients are younger than those in advanced countries as well (6). About 15% of women with familial breast cancer are implicated to have mutation in BRCA1 and BRCA2 genes, also, all women with ovarian cancer are affected by some mutation in these genes (7).
The BRCA1 was first identified by linkage analysis on chromosome 17q21 in 1994 (2). An autosomal hereditary pattern is linked to BRCA1 in some cases (8). BRCA1 gene consists of 24 exons that encode a protein with 1863 amino acids with three major functional domains and a ubiqitin ligase domain named as: RING domain; at the N-terminus, nuclear localization signal domain (NLS) in the middle and BRCT (BRCA1 C-terminal domain at C-terminus, respectively (9). Familial mutation may be hereditary, while screening and detection of mutations in BRCA1 gene may help in medical
Table VI. Comparison of other prevalence haplotypes in breast cancer patients and control group
94-147-5/table_4.jpg)
In this study, the haplotyping of intragenic markers of BRCA1 were evaluated. Main conclusion of this study is that four haplotypes can be evaluated between breast cancer patients and healthy women for D17S855 and D17S1322 respectively, 1) 146, 121; 2) 146, 142; 3) 150, 121; 4) 150, 142. Two out of four possible haplotypes were significant in patients, which showed increased risks for breast/ovarian cases with either of these two haplotypes (RR of 1.6 and 1.92 for both haplotypes, respectively) (p<0.01). The proportion of 121 and 150 haplotypes in experimental subjects were approximately twice in numbers when compared with the prevalence in controls. Also, other tri-allelic haplotypes in patients had significant relative risk. As illustrated in table IV, the proportion of 144, 152, 112 and 148, 150, 121 haplotypes in studied patients were approximately twice in number when compared with prevalence in controls.
Nowacka-Zawisza et al showed that polymorphism of di-nucleotide CA repeat at RAD51 and BRCA2 gene regions might be associated with genetic susceptibility to breast cancer (20). Also, in another study, BRCA1 mutations were defined by presence of BRCA1 intragenic STR markers. de la Hoya et al suggested that mutation on BRCA1 were correlated with two alleles of D17S855 (139 and 141bp) in Spanish population (22).
While, our study indicated that in Iranian population, the breast cancer susceptibility is not randomly distributed but it is clustered in subset of BRCA1 alleles that can be identified by D17S855 and D17S1322 genotyping. Osorio et al observed one specific allele for microsatellite marker D17S855, which are also more frequently associated with BRCA1 mutations (18). In Malaya patientsBRCA1 was found to have a deleterious mutation, c.2845insA, which was associated with STR haplotype, 142-127-159 for D17S855, D17S1322 and D17S323, respectively (11).
The BRCA1 mutation at c.5266dupC is originally a founder mutation in the Ashkenazi Jewish population, and same mutation is also found in several different population groups such as Russian, Latvian, Ukrainian, Czech, Slovak, Polish, Danish, Dutch, French, German, Italian, Greek, Brazilian and Azerbaijan. Haplotyping by microsatellite markers confirmed that all mutation carriers shared a common BRCA1 STR haplotype (10, 23).
Conclusion
In conclusion, screening of microsatellite polymorphism of DNA repairing genes in families with breast cancer history can be useful tool for prognosis, incidence and occurrence of breast cancer in healthy women/men. Therefore, assessment of presence or absence of mentioned haplotype in the BRCA1 microsatellites can be used for prognosis in individuals, suspected of having or not having breast cancer.
Acknowledgments
The present project was supported by a grants from the Research Foundation of the University of Sistan and Baluchestan, Zahedan, Iran, Science and Technology Park, Yazd, Iran and Research and Clinical Centre for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Conflict of interest
There is no conflict of interest in this study.
Breast cancer is responsible for a large amount of mortality rate in women worldwide. Hereditary Breast and Ovarian Cancer is a syndrome that increases the lifetime risk for developing breast and/or ovarian cancer and other malignancies in women. Inheritance of this syndrome is usually based on germ-line mutation in one allele of either the Breast Cancer Type 1 Susceptibility (BRCA1) or Breast Cancer Type 2 Susceptibility (BRCA2) genes (1-4). In American society, more than 1.5 million new breast cancer cases occurred in 2014 (5). In Iranian society, lifetime prevalence of breast cancer is one in eight female cases and the breast cancer patients are younger than those in advanced countries as well (6). About 15% of women with familial breast cancer are implicated to have mutation in BRCA1 and BRCA2 genes, also, all women with ovarian cancer are affected by some mutation in these genes (7).
The BRCA1 was first identified by linkage analysis on chromosome 17q21 in 1994 (2). An autosomal hereditary pattern is linked to BRCA1 in some cases (8). BRCA1 gene consists of 24 exons that encode a protein with 1863 amino acids with three major functional domains and a ubiqitin ligase domain named as: RING domain; at the N-terminus, nuclear localization signal domain (NLS) in the middle and BRCT (BRCA1 C-terminal domain at C-terminus, respectively (9). Familial mutation may be hereditary, while screening and detection of mutations in BRCA1 gene may help in medical
management of patients and their families. BRCA1 haplotype analysis was carried out to estimate the ancestral origin of mutations and haplotypes associated with particular diseases (10, 11). Founder mutation analysis performed using haplotype assessment to find the first carrier of mutation, in several population founder mutation have been originated (12-16). Genetic polymorphism of tumor suppressor and DNA repair genes have been involved in breast cancer risk (17).
In some clinically investigated genes, the intragenic marker polymorphism is the most important. In screening of large genes, it is difficult to select patients carrying such mutations (18). Screening of BRCA1 mutation is carried out much faster by using short tandem repeat (STR) polymorphism. Individual polymorphism of STR is a good evidence of following the inheritance of repeat polymorphism. Several markers exist within the flanking BRCA1. D17S1323 (intron 12), D17S1322 (intron 19), and D17S855 (intron 20); were genotyped at the 3′ end of BRCA1 gene. D17S855 and D17S1323 are di-nucleotide STR and D17S1322 is a tri-nucleotide repeat (19, 20).
Our main goal was to evaluate haplotyping of three intragenic markers of BRCA1 between breast cancer patients and healthy women.
Materials and methods
This case-control study was carried out in Science and Arts University, Yazd, Iran. The study protocol was approved by the Ethics Committee of Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Written informed consent was obtained from all participants.
107 women aged 36-51 years with breast or ovarian cancer who were admitted to Yazd hospitals between January 2014 to July 2015 were enrolled as case group. Diagnosis was confirmed in all patients with pathologic findings. Information regarding family history of cancer and other relevant clinical details was available in case group.
The control-group members (n=93) were age-matched unrelated normal healthy women that inhabit in yazd and had no history of breast cancer or other cancers in their family members. Peripheral blood samples were collected in Ethylenediaminetetraacetic acid (EDTA) from all participants. Genomic DNA was extracted from peripheral blood using Prime Prep kit (Cat.k-2000, Genet Bio, Korea) according to the manufacturer′s protocol.
PCR program
The genomic intragenic amplicons of di/tri- nucleotides of BRCA1 genes were individually amplified by PCR procedure. For PCR amplification, three sets of primer pairs were used to amplify three intragenic markers of BRCA1 gene. PCR amplification for a 25 µL PCR reaction volume was used. The PCR mixture consisted of 12.5µL of Taq 2X Master Mix RED (cat.A180301, Ampliqon), 9.5 µL of water and 2.0 µL of primer mix. To make the final reaction volume, 1.0 µL DNA was also added. The PCR reaction was run with an initial denaturation at 94oC for 4 min, followed by 32 cycles of denaturation at 94oC for 30 sec, while the annealing temperature was specific for each primer for 30 sec and the extension at 72oC for 1 min. Final extension was carried out for 10 min at 72oC. Primers were designed by Sci-Ed Software (Table I) (21).
Fragment analysis
For STR analysis, forward primers of each pair of primers were labeled with FAM, HEX and TAMRA for D17S1322, D17S1323 and D17S855, respectively. The samples were read on ABI Prism 3730xl using Genemarker Software (version 2.6.3).
Statistical analysis
All statistical analyses were carried out using the IBM SPSS (version 22.0) software. A non-parametric c2 test was used to compare the differences between two groups. Statistical significance was accepted at p<0.05.
Results
Haplotype assessments were carried out by fragment analysis. Haplotype analysis was performed with 3 intragenic polymorphic markers (D17S855, D17S1322 and D17S1323), located in introns 20, 19 and 12, respectively. STR heliotyping was carried out using fragment analysis. It was observed that D17S1323 had 11 allels (Table II) and D17S855 had 11 alleles (Table III). Also, D17S1322 had 13 alleles (Table VI). There was significant difference in two alleles of D17S855: allele 146 (p=0.02) and 150 (p=0.006); and two allele of D17S1322: allele 121 (p=0.015) and 142 (p=0.043), as compared to control group.
94-147-5/table_2.jpg)
Table III. Allele distribution of the D17S855 in Iranian women with breast/ovarian cancer (p-value with significance is in bold)
94-147-5/table_3.jpg)
In some clinically investigated genes, the intragenic marker polymorphism is the most important. In screening of large genes, it is difficult to select patients carrying such mutations (18). Screening of BRCA1 mutation is carried out much faster by using short tandem repeat (STR) polymorphism. Individual polymorphism of STR is a good evidence of following the inheritance of repeat polymorphism. Several markers exist within the flanking BRCA1. D17S1323 (intron 12), D17S1322 (intron 19), and D17S855 (intron 20); were genotyped at the 3′ end of BRCA1 gene. D17S855 and D17S1323 are di-nucleotide STR and D17S1322 is a tri-nucleotide repeat (19, 20).
Our main goal was to evaluate haplotyping of three intragenic markers of BRCA1 between breast cancer patients and healthy women.
Materials and methods
This case-control study was carried out in Science and Arts University, Yazd, Iran. The study protocol was approved by the Ethics Committee of Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Written informed consent was obtained from all participants.
107 women aged 36-51 years with breast or ovarian cancer who were admitted to Yazd hospitals between January 2014 to July 2015 were enrolled as case group. Diagnosis was confirmed in all patients with pathologic findings. Information regarding family history of cancer and other relevant clinical details was available in case group.
The control-group members (n=93) were age-matched unrelated normal healthy women that inhabit in yazd and had no history of breast cancer or other cancers in their family members. Peripheral blood samples were collected in Ethylenediaminetetraacetic acid (EDTA) from all participants. Genomic DNA was extracted from peripheral blood using Prime Prep kit (Cat.k-2000, Genet Bio, Korea) according to the manufacturer′s protocol.
PCR program
The genomic intragenic amplicons of di/tri- nucleotides of BRCA1 genes were individually amplified by PCR procedure. For PCR amplification, three sets of primer pairs were used to amplify three intragenic markers of BRCA1 gene. PCR amplification for a 25 µL PCR reaction volume was used. The PCR mixture consisted of 12.5µL of Taq 2X Master Mix RED (cat.A180301, Ampliqon), 9.5 µL of water and 2.0 µL of primer mix. To make the final reaction volume, 1.0 µL DNA was also added. The PCR reaction was run with an initial denaturation at 94oC for 4 min, followed by 32 cycles of denaturation at 94oC for 30 sec, while the annealing temperature was specific for each primer for 30 sec and the extension at 72oC for 1 min. Final extension was carried out for 10 min at 72oC. Primers were designed by Sci-Ed Software (Table I) (21).
Fragment analysis
For STR analysis, forward primers of each pair of primers were labeled with FAM, HEX and TAMRA for D17S1322, D17S1323 and D17S855, respectively. The samples were read on ABI Prism 3730xl using Genemarker Software (version 2.6.3).
Statistical analysis
All statistical analyses were carried out using the IBM SPSS (version 22.0) software. A non-parametric c2 test was used to compare the differences between two groups. Statistical significance was accepted at p<0.05.
Results
Haplotype assessments were carried out by fragment analysis. Haplotype analysis was performed with 3 intragenic polymorphic markers (D17S855, D17S1322 and D17S1323), located in introns 20, 19 and 12, respectively. STR heliotyping was carried out using fragment analysis. It was observed that D17S1323 had 11 allels (Table II) and D17S855 had 11 alleles (Table III). Also, D17S1322 had 13 alleles (Table VI). There was significant difference in two alleles of D17S855: allele 146 (p=0.02) and 150 (p=0.006); and two allele of D17S1322: allele 121 (p=0.015) and 142 (p=0.043), as compared to control group.
Table I. Primer sequences for BRCA1 haplotype analysis
94-147-5/table_1.jpg)
Table II. Allele distribution of the D17S1323 in Iranian women with breast/ovarian cancer
Table III. Allele distribution of the D17S855 in Iranian women with breast/ovarian cancer (p-value with significance is in bold)
Table VI. Comparison of other prevalence haplotypes in breast cancer patients and control group
a Prevalence of haplotype in percentage bChi-square, with statistical significance if p<0.05 c Relative risk
In this study, the haplotyping of intragenic markers of BRCA1 were evaluated. Main conclusion of this study is that four haplotypes can be evaluated between breast cancer patients and healthy women for D17S855 and D17S1322 respectively, 1) 146, 121; 2) 146, 142; 3) 150, 121; 4) 150, 142. Two out of four possible haplotypes were significant in patients, which showed increased risks for breast/ovarian cases with either of these two haplotypes (RR of 1.6 and 1.92 for both haplotypes, respectively) (p<0.01). The proportion of 121 and 150 haplotypes in experimental subjects were approximately twice in numbers when compared with the prevalence in controls. Also, other tri-allelic haplotypes in patients had significant relative risk. As illustrated in table IV, the proportion of 144, 152, 112 and 148, 150, 121 haplotypes in studied patients were approximately twice in number when compared with prevalence in controls.
Nowacka-Zawisza et al showed that polymorphism of di-nucleotide CA repeat at RAD51 and BRCA2 gene regions might be associated with genetic susceptibility to breast cancer (20). Also, in another study, BRCA1 mutations were defined by presence of BRCA1 intragenic STR markers. de la Hoya et al suggested that mutation on BRCA1 were correlated with two alleles of D17S855 (139 and 141bp) in Spanish population (22).
While, our study indicated that in Iranian population, the breast cancer susceptibility is not randomly distributed but it is clustered in subset of BRCA1 alleles that can be identified by D17S855 and D17S1322 genotyping. Osorio et al observed one specific allele for microsatellite marker D17S855, which are also more frequently associated with BRCA1 mutations (18). In Malaya patientsBRCA1 was found to have a deleterious mutation, c.2845insA, which was associated with STR haplotype, 142-127-159 for D17S855, D17S1322 and D17S323, respectively (11).
The BRCA1 mutation at c.5266dupC is originally a founder mutation in the Ashkenazi Jewish population, and same mutation is also found in several different population groups such as Russian, Latvian, Ukrainian, Czech, Slovak, Polish, Danish, Dutch, French, German, Italian, Greek, Brazilian and Azerbaijan. Haplotyping by microsatellite markers confirmed that all mutation carriers shared a common BRCA1 STR haplotype (10, 23).
Conclusion
In conclusion, screening of microsatellite polymorphism of DNA repairing genes in families with breast cancer history can be useful tool for prognosis, incidence and occurrence of breast cancer in healthy women/men. Therefore, assessment of presence or absence of mentioned haplotype in the BRCA1 microsatellites can be used for prognosis in individuals, suspected of having or not having breast cancer.
Acknowledgments
The present project was supported by a grants from the Research Foundation of the University of Sistan and Baluchestan, Zahedan, Iran, Science and Technology Park, Yazd, Iran and Research and Clinical Centre for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Conflict of interest
There is no conflict of interest in this study.
Type of Study: Original Article |
References
1. Raičević-Maravić L, Radulović S. Breast cancer susceptibility Gene 2-BRCA2. Arch Oncol 2001; 9: 115-118.
2. Miki Y, Swensen J, Shattuck-eidens D, Futreal PA, Harshman K, Tavtigian S, et al. Strong Candidate for the Breast and Ovarian Cancer. Science 1994; 266: 66-71. [DOI:10.1126/science.7545954]
3. Alsop K, Fereday S, Meldrum C, DeFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian ovarian cancer study group. J Clin Oncol 2012; 30: 2654-2663. [DOI:10.1200/JCO.2011.39.8545]
4. Li ML A, Greenberg R. Links between genome integrity and BRCA1 tumor suppression. Trends Biochem Sci 2012; 37: 418-424. [DOI:10.1016/j.tibs.2012.06.007]
5. Siegel R, Ma J, Zou Z, Jemal A. Cancer Statistics, 2014. CA Cancer J Clin 2014; 64: 9-29. [DOI:10.3322/caac.21208]
6. Karami F, Mehdipour P. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. BioMed Res Int 2013; ID 928562.
7. Couch FJ, Nathanson KL, Offit K. Two Decades After BRCA: Setting Paradigms in Personalized Cancer Care and Prevention. Science 2014; 343: 1466-1470. [DOI:10.1126/science.1251827]
8. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994; 73: 643-651.
https://doi.org/10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5 [DOI:10.1002/1097-0142(19940201)73:33.0.CO;2-5]
9. Clark SL, Rodriguez AM, Snyder RR, Hankins GDV, Boehning D. Structure-Function Of The Tumor Suppressor BRCA1. Comp Struct Biotech J 2012; 1: 1-8. [DOI:10.5936/csbj.201204005]
10. Laitman Y, Feng B-J, Zamir IM, Weitzel JN, Duncan P, Port D, et al. Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. Eur J Hum Genet 2013; 21: 212-216. [DOI:10.1038/ejhg.2012.124]
11. Ali AB, Iau PT, Putti TC, Sng JH. BRCA1 disease-associated haplotypes in Singapore Malay women with early-onset breast/ovarian cancer. Breast Cancer Res Treatment 2007; 104: 351-313. [DOI:10.1007/s10549-006-9467-6]
12. Russo A, Calò V, Augello C, Bruno L, Agnese V, Schirò V, et al. 4843delC of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily). Annal Oncol 2007; 18(Suppl.): 99-102. [DOI:10.1093/annonc/mdm235]
13. Ferla R, Calò V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, et al. Founder mutations in BRCA1 and BRCA2 genes. Annal Oncol 2007; 18 (Suppl.): 93-98. [DOI:10.1093/annonc/mdm234]
14. Sidoni T, Cocciolone V, Giannini G, Russo a., Baudi F, Cannita K, et al. Identification and Characterization of BRCA1 and BRCA2 Founder Mutations. Current Women's Health Rev 2012; 8: 17-22. [DOI:10.2174/157340412799079192]
15. Anagnostopoulos T, Pertesi M, Konstantopoulou I, Armaou S, Kamakari S, Nasioulas G, et al. G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: Evaluation of its pathogenicity and inferences on its genealogical history. Breast Cancer Res Treatment 2008; 110: 377-385. [DOI:10.1007/s10549-007-9729-y]
16. Janavičius R. Founder BRCA1/2 mutations in the Europe: Implications for hereditary breast-ovarian cancer prevention and control. EPMA J 2010; 1: 397-412. [DOI:10.1007/s13167-010-0037-y]
17. Bardia A, Tiwari SK, Vishwakarma SK, Habeeb MA, Nallari P, Sultana SA, et al. Haplotype Analyses of DNA Repair Gene Polymorphisms and Their Role in Ulcerative Colitis. Plos One 2014; 9: e108562. [DOI:10.1371/journal.pone.0108562]
18. Osorio A, de la Hoya M, Rodríguez-López R, Granizo JJ, Díez O, Vega A, et al. Over-representation of two specific haplotypes among chromosomes harbouring BRCA1 mutations. Eur J Hum Genet 2003; 11: 489-492. [DOI:10.1038/sj.ejhg.5200969]
19. Mefford HC, Baumbach L, Panguluri RC, Whitfield-Broome C, Szabo C, Smith S, et al. Evidence for a BRCA1 founder mutation in families of West African ancestry. Am J Hum Genet 1999; 65: 575-578. [DOI:10.1086/302511]
20. Nowacka-Zawisza M, Brys M, Romanowicz-Makowska H, Kulig A, Krajewska WM. Dinucleotide repeat polymorphisms of RAD51, BRCA1, BRCA2 gene regions in breast cancer. Pathol Int 2008; 58: 275-281. [DOI:10.1111/j.1440-1827.2008.02223.x]
21. Pestonjamasp PH, Mittra I. Analysis of BRCA1 involvement in breast cancer in Indian women. J Biosci 2000; 25: 19-23. [DOI:10.1007/BF02985177]
22. De La Hoya M, Sulleiro S, Osorio A, Díez O, Baiget M, Benítez J, et al. Clustering of cancer-related mutations in a subset of BRCA1 alleles: A study in the Spanish population. Int J Cancer 2002; 100: 618-619. [DOI:10.1002/ijc.10527]
23. Hamel N, Feng B-J, Foretova L, Stoppa-Lyonnet D, Narod S a, Imyanitov E, et al. On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. Eur J Hum Genet 2011; 19: 300-306. [DOI:10.1038/ejhg.2010.203]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
